TERMINATION AND REVISED RELATIONSHIP AGREEMENTTermination and Revised Relationship Agreement • June 5th, 2023 • MEI Pharma, Inc. • Pharmaceutical preparations • New York
This Termination and Revised Relationship Agreement (this “Agreement”) is entered into as of the 17th day of July 2012 (the “Effective Date”) by and between Infinity Pharmaceuticals, Inc., a Delaware corporation having its principal office at 780 Memorial Drive, Cambridge, Massachusetts 02139 (“Infinity”), and Purdue Pharmaceutical Products L.P., a Delaware limited partnership (“Purdue”).
TERMINATION AND REVISED RELATIONSHIP AGREEMENTTermination and Revised Relationship Agreement • June 5th, 2023 • MEI Pharma, Inc. • Pharmaceutical preparations • New York
This Termination and Revised Relationship Agreement (this “Agreement”) is entered into as of the 17 th day of July 2012 (the “Effective Date”) by and between Infinity Pharmaceuticals, Inc., a Delaware corporation having its principal office at 780 Memorial Drive, Cambridge, Massachusetts 02139 (“Infinity”), and Mundipharma International Corporation Limited, a Bermuda corporation having its principal office at Mundipharma House, 14 Par-la-Ville Road, P.O. Box HM 2332, Hamilton HM JX, Bermuda (“MICL”).
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. TERMINATION AND REVISED RELATIONSHIP AGREEMENTTermination and Revised Relationship Agreement • August 10th, 2012 • Novartis Ag • Pharmaceutical preparations • New York
